Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important Gram-positive pathogen in both the hospital and outpatient settings. The recent FDA approvals of oritavancin (The…
Through comprehensive primary research methods, the TreatmentTrends: Rheumatoid Arthritis 2015 (US) report explores the treatment dynamics among 100 U.S. rheumatologists and how these have evolved…
The 2014 multiple myeloma market garnered impressive sales despite its relatively low incidence compared with other oncology markets with similar revenues. Significant achievements in clinical…
Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in…
TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema (EU) is the inaugural report in an annual syndicated report series that offers a snapshot of the diabetic retinopathy (DR) and diabetic…
Last Updated 8 December 2015 The hepatitis C virus (HCV) therapy market is undergoing unprecedented growth. Commercial opportunity is driven by a large prevalent population and historically high…
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and axial skeleton, causing pain and greatly impacting quality of life. Diagnosis can be difficult,…
For the estimated 14.5 million diagnosed prevalent cases of asthma in the United States, there are multiple prescription therapies that are available for treating the associated symptoms. The…
Four novel prescription weight-loss agents have launched in the United States since 2012: Vivus’s Qsymia (phentermine/topiramate ER), Arena Pharmaceuticals/Eisai’s Belviq (lorcaserin),…
Last Updated 4 December 2015 The term dyslipidemia refers to abnormalities in the composition, concentration, or size of lipoproteins in the circulation. Dyslipidemia is a key modifiable risk…
LaunchTrends: Keytruda Wave 3 (US) is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the malignant melanoma drug…
The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg 3TW, oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision-making and treatment choice in the…
Despite the extensive armamentarium of chronic pain therapies—and the fact that the market is increasingly subject to generics competition—the chronic pain market continues to represent a…
Bipolar disorder (BPD) is a debilitating psychiatric illness affecting more than 20 million people across the seven major pharmaceutical markets under study (United States, France, Germany, Italy,…
Bipolar disorder (BPD) is a debilitating psychiatric illness affecting more than 20 million people across the seven major pharmaceutical markets under study (United States, France, Germany, Italy,…